WO2003066095A3 - MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING - Google Patents

MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING Download PDF

Info

Publication number
WO2003066095A3
WO2003066095A3 PCT/NL2003/000087 NL0300087W WO03066095A3 WO 2003066095 A3 WO2003066095 A3 WO 2003066095A3 NL 0300087 W NL0300087 W NL 0300087W WO 03066095 A3 WO03066095 A3 WO 03066095A3
Authority
WO
WIPO (PCT)
Prior art keywords
modulating
tolerance
fcϝriib
receptor signalling
antigen
Prior art date
Application number
PCT/NL2003/000087
Other languages
French (fr)
Other versions
WO2003066095A2 (en
Inventor
Janneke Nicoline Samsom
Reina Elizabeth Mebius
Helvoort Johannes Martinus Van
George Kraal
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Janneke Nicoline Samsom
Reina Elizabeth Mebius
Helvoort Johannes Martinus Van
George Kraal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs, Janneke Nicoline Samsom, Reina Elizabeth Mebius, Helvoort Johannes Martinus Van, George Kraal filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Priority to AU2003206264A priority Critical patent/AU2003206264A1/en
Publication of WO2003066095A2 publication Critical patent/WO2003066095A2/en
Publication of WO2003066095A3 publication Critical patent/WO2003066095A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the field of immunology and medicine. It particularly relates to a method for modulating tolerance to an antigen involved in an allergic reaction or in an autoimmune disorder or an antigen used in a vaccine. The invention provides a method for modulating tolerance to an antigen involved in an allergic reaction or in an autoimmune disorder or an antigen used in a vaccine comprising providing a ligand capable of modulating FcϜRIIB receptor signalling.
PCT/NL2003/000087 2002-02-07 2003-02-07 MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING WO2003066095A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003206264A AU2003206264A1 (en) 2002-02-07 2003-02-07 MODULATING TOLERANCE BY MODULATING FcGammaRIIB RECEPTOR SIGNALLING

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075521 2002-02-07
EP02075521.1 2002-02-07

Publications (2)

Publication Number Publication Date
WO2003066095A2 WO2003066095A2 (en) 2003-08-14
WO2003066095A3 true WO2003066095A3 (en) 2003-12-31

Family

ID=27675702

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2003/000087 WO2003066095A2 (en) 2002-02-07 2003-02-07 MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING

Country Status (2)

Country Link
AU (1) AU2003206264A1 (en)
WO (1) WO2003066095A2 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8951517B2 (en) 2003-01-09 2015-02-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425619B2 (en) 2002-08-14 2008-09-16 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
PL2029173T3 (en) 2006-06-26 2017-04-28 Macrogenics, Inc. Fc riib-specific antibodies and methods of use thereof
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
US10507234B2 (en) 2015-07-17 2019-12-17 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with Fc-coupled antigens
KR102514317B1 (en) 2016-04-15 2023-03-27 마크로제닉스, 인크. Novel B7-H3-binding molecules, antibody drug conjugates thereof and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
OTT VANESSA L ET AL: "FcgammaRIIB as a potential molecular target for intravenous gamma globulin therapy.", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 108, no. 4 Supplement, October 2001 (2001-10-01), pages S95 - S98, XP008008611, ISSN: 0091-6749 *
RAVETCH JEFFREY V ET AL: "IgF Fc receptors.", ANNUAL REVIEW OF IMMUNOLOGY, vol. 19, 2001, 2001 Annual Reviews 4139 El Camino Way, Palo Alto, CA, 94303-0139, USA, pages 275 - 290, XP008008612, ISBN: 0-8243-3019-6 *
RAVETCH JEFFREY V: "Fc receptors: Activation-inhibition receptor pairing.", ACTIVATING AND INHIBITORY IMMUNOGLOBULIN-LIKE RECEPTORS., 2001, CREST International Symposium on Immunoglobulin-like Receptors;Sendai City, Japan; September 18-19, 2000, Springer-Verlag Tokyo Inc.;Springer-Verlag New York Inc. 3-13 Hongo 3-chome, Bunkyo-ku, Tokyo,, pages 1 - 4, XP008008610, ISBN: 4-431-70297-0 *
SAMUELSSON ASTRID ET AL: "Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor.", SCIENCE (WASHINGTON D C), vol. 291, no. 5503, 2001, pages 484 - 486, XP002215958, ISSN: 0036-8075 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8951517B2 (en) 2003-01-09 2015-02-10 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8993730B2 (en) 2008-04-02 2015-03-31 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
US9243069B2 (en) 2008-04-02 2016-01-26 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using the same
US9469692B2 (en) 2008-04-02 2016-10-18 Macrogenics, Inc. HER2/neu-specific antibodies and methods of using same
US9096877B2 (en) 2009-10-07 2015-08-04 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
US9150656B2 (en) 2010-03-04 2015-10-06 Macrogenics, Inc. Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof
US9441049B2 (en) 2010-03-04 2016-09-13 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof

Also Published As

Publication number Publication date
AU2003206264A1 (en) 2003-09-02
WO2003066095A2 (en) 2003-08-14
AU2003206264A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
WO2003066095A3 (en) MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING
WO2003030835A3 (en) Use of bispecific antibodies to regulate immune responses
SG135207A1 (en) Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them
PL1469369T3 (en) Verbose hardware identification for binding a software package to a computer system having tolerance for hardware changes
ZA200507067B (en) Antibodies against human IL-21 receptor and uses therefor
AU2003287620A1 (en) Healthcare verification methods, apparatus and systems
DE602004020901D1 (en) System for the introduction of several medical devices
WO2005115522A3 (en) Medical device systems
HK1135431A1 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
EP1681984A4 (en) Transesophageal gastric reduction device, system and method
NL1021593A1 (en) Method for determining the degree of acoustic confusion, and a system for that.
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
WO2005010048A3 (en) Rg1 antibodies and uses thereof
WO2006066003A3 (en) Methods and compositions for induction or promotion of immune tolerance
WO2006083792A3 (en) Novel polypeptide ligands for toll-like receptor 2 (tlr2)
WO2008130382A3 (en) Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
IL172707A0 (en) Data input device, system using the device, and methods for operating such systems
WO2004060295A3 (en) Methods of inducing and maintaining immune tolerance
AU2003243914A1 (en) Microparticle with cd28-specific monoclonal antibodies
SI1572087T1 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004046188A3 (en) Anti-activated ras antibodies
DE60238555D1 (en) PARATHORMONE ANTIBODIES AND ASSOCIATED METHODS
NL1027798A1 (en) System and method for data slip ring connection.
AU2002309486A1 (en) Methods and compositions for modulating the immune system of animals
AU2003234443A1 (en) Use of anti-cd1 antibodies for the modulation of immune responses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP